The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer
Open accessAbstract
In pancreatic cancer (PC) accurate determination of treatment response by imaging often remains difficult. Various efforts have been undertaken to investigate new factors which may serve as more appropriate surrogate parameters of treatment efficacy. This review focuses on the role of carbohydrate antigen 19-9 (CA 19-9) as a prognostic tumor marker in PC and summarizes its contribution to monitoring treatment efficacy. We undertook a Medline/PubMed literature search to identify relevant trials that had analyzed the prognostic impact of CA 19-9 in patients treated with surgery, chemoradiotherapy and chemotherapy for PC. Additionally, relevant abstract publications from scientific meetings were included. In advanced PC, pretreatment CA 19-9 levels have a prognostic impact regarding overall survival. Also a CA 19-9 decline under chemotherapy can provide prognostic information for median survival. A 20% reduction of CA 19-9 baseline levels within the first 8 weeks of chemotherapy appears to be sufficient to define a prognostic relevant subgroup of patients (‘CA 19-9 responder’). It still remains to be defined whether the CA 19-9 response is a more reliable method for evaluating treatment efficacy compared to conventional imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Molecular markers of early pancreatic cancer
Goggins, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.711 · Cited by 214
Cited by
Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju413 · Cited by 658
Self-citationFabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
E. Poruk, K., Z. Gay, D., Brown, K., D. Mulvihill, J., M. Boucher, K., L. Scaife, C., A. Firpo, M., & J. Mulvihill, S. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313030003 · Cited by 398
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
Duffy, M. J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V. L., Klapdor, R., Nicolini, A., Topolcan, O., & Heinemann, V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp332 · Cited by 381
Self-citationThe prognostic and predictive value of serum CA19.9 in pancreatic cancer
Humphris, J. L., Chang, D. K., Johns, A. L., Scarlett, C. J., Pajic, M., Jones, M. D., Colvin, E. K., Nagrial, A., Chin, V. T., Chantrill, L. A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr561 · Cited by 312
Metadata
- Authors
- Boeck, S., Stieber, P., Holdenrieder, S., Wilkowski, R., & Heinemann, V.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2006
- Volume
- 70
- Issue
- 4
- Pages
- 255-264
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2091119990
- Cited by
- 172
- References
- 2
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. https://app.cochat.ai/papers/10.1159/000094888
- The paper
- Boeck, S., Stieber, P., Holdenrieder, S., Wilkowski, R., & Heinemann, V. (2006). Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. Oncology. https://doi.org/10.1159/000094888
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.